{"id":"abadf566-b528-4b44-be3e-418ca078e920","companyId":"a3a097cb-a5db-4ffd-b421-5eb14335dbcf","modelName":"Senhance","slug":"asensus-senhance","description":"Asensus Surgical, formerly TransEnterix and based in Durham, North Carolina, was a public company on the NYSE American as ASXC that made the Senhance multi-port laparoscopic robotic system, FDA-cleared via 510(k) in October 2017 with subsequent instrument and indication clearances, making Senhance a genuinely cleared if relatively low-volume commercial product. The headline current-state fact is that Karl Storz acquired the company, closing on August 22, 2024 at $0.35 per share for about $95 million, a roughly 67 percent premium, with the stock ceasing to trade on the NYSE American at close, leaving Asensus a private Karl Storz subsidiary; this is the canonical example of a large medtech company absorbing a struggling robotics startup for a fraction of its historic enterprise value. The registry records Senhance at commercial maturity with an active lifecycle, since it remains a cleared product line continuing under Karl Storz, while the company status is recorded as acquired. The company's next-generation LUNA system, unveiled in February 2023 with claimed real-time clinical intelligence and cloud machine learning, was not FDA-submitted, not cleared, and not for sale as of the August 2024 close, so LUNA is recorded at research maturity, with a 2025 FDA target that is unverified as met and a current status under private ownership that is not publicly traceable. On AI substance the cleared digital-surgery features are machine-vision and digital-laparoscopy assists that are real but incremental rather than autonomy, and the Performance-Guided Surgery framing was oversold relative to what is cleared.","formFactor":"surgical","maturityStage":"commercial","lifecycleState":"active","supersededByModelId":null,"specs":{"notes":[{"label":"Verified","value":"Asensus Surgical (formerly TransEnterix; Durham NC; was NYSE American: ASXC) made the Senhance laparoscopic robot, FDA-cleared via 510(k) in Oct 2017 with subsequent clearances/indication expansions. Senhance is a genuinely cleared, commercial (if low-volume) product."},{"label":"Current status: ACQUIRED by Karl Storz (the headline)","value":"Karl Storz acquired 100% of Asensus, closing Aug 22 2024 at $0.35/share (~$95M total, ~67% premium); the stock ceased trading on NYSE American at close (delisted; now a private Karl Storz subsidiary). The canonical big-medtech-acquires-struggling-robotics-startup datapoint: a former public-market name sold for a fraction of its historic enterprise value. maturityStage=commercial (Senhance is cleared + still a product line); company status=acquired; lifecycleState=active (Senhance line continues under Karl Storz)."},{"label":"LUNA = research","value":"The next-gen LUNA (real-time 'clinical intelligence' + cloud ML) was NOT FDA-submitted / NOT cleared / NOT for sale as of the Aug 2024 close. Karl Storz had targeted 2025 FDA - that target is unverified as met. LUNA = research-tier; current status under private-owner Karl Storz is not publicly traceable (cap-flag)."},{"label":"AI-substance + claimed-not-verified","value":"Cleared 'digital surgery' substance = machine-vision/digital-laparoscopy assists (real but incremental, not autonomy); 'Performance-Guided Surgery' framing oversold vs what's cleared. NOT verified: LUNA FDA submission/clearance ever occurring; current Senhance installed-unit count (Karl Storz private); whether Senhance is actively commercialized vs wound down under Karl Storz."}],"products":"Senhance: FDA-cleared multi-port laparoscopic robotic system (initial 510(k) Oct 2017 as TransEnterix; later 3mm instruments, ultrasonic, indication expansions, machine-vision clearance). LUNA: next-gen system (unveiled Feb 2023) with claimed real-time clinical intelligence + cloud ML; NOT FDA-submitted/cleared, NOT for sale.","formFactor":"surgical (multi-port laparoscopic teleoperated robotic system with machine-vision/digital-laparoscopy assists)"},"manufacturerSerial":null,"reviewStatus":"reviewed","sources":[{"url":"https://www.globenewswire.com/news-release/2024/08/22/asensus-surgical-karl-storz-closing","title":"Asensus Surgical: closing of acquisition by Karl Storz ($0.35/sh, ~$95M; delisted; LUNA not cleared)","sourceName":"Asensus (GlobeNewswire)"},{"url":"https://www.massdevice.com/asensus-surgical-karl-storz-acquisition/","title":"Asensus agrees to be acquired by Karl Storz (~$95M, 67% premium)","sourceName":"MassDevice"},{"url":"https://www.urologytimes.com/view/transenterix-senhance-fda-clearance","title":"TransEnterix (Asensus) Senhance US FDA 510(k) clearance (Oct 2017)","sourceName":"Urology Times"},{"url":"https://www.therobotreport.com/karl-storz-closes-acquisition-of-asensus-surgical/","title":"Karl Storz closes acquisition of Asensus Surgical (Aug 2024)","sourceName":"The Robot Report"}],"aliases":["Senhance","Asensus Senhance","TransEnterix Senhance","LUNA"],"collisionRisk":"low","reviewNote":null,"manufacturerTermForTeleop":null,"createdAt":"2026-06-03T20:12:50.702Z","updatedAt":"2026-06-03T20:12:50.702Z","jsonLd":{"@context":"https://schema.org","@type":"Product","@id":"https://registry.deploy.report/models/asensus-senhance","url":"https://registry.deploy.report/models/asensus-senhance","name":"Senhance","alternateName":["Senhance","Asensus Senhance","TransEnterix Senhance","LUNA"],"description":"Asensus Surgical, formerly TransEnterix and based in Durham, North Carolina, was a public company on the NYSE American as ASXC that made the Senhance multi-port laparoscopic robotic system, FDA-cleared via 510(k) in October 2017 with subsequent instrument and indication clearances, making Senhance a genuinely cleared if relatively low-volume commercial product. The headline current-state fact is that Karl Storz acquired the company, closing on August 22, 2024 at $0.35 per share for about $95 million, a roughly 67 percent premium, with the stock ceasing to trade on the NYSE American at close, leaving Asensus a private Karl Storz subsidiary; this is the canonical example of a large medtech company absorbing a struggling robotics startup for a fraction of its historic enterprise value. The registry records Senhance at commercial maturity with an active lifecycle, since it remains a cleared product line continuing under Karl Storz, while the company status is recorded as acquired. The company's next-generation LUNA system, unveiled in February 2023 with claimed real-time clinical intelligence and cloud machine learning, was not FDA-submitted, not cleared, and not for sale as of the August 2024 close, so LUNA is recorded at research maturity, with a 2025 FDA target that is unverified as met and a current status under private ownership that is not publicly traceable. On AI substance the cleared digital-surgery features are machine-vision and digital-laparoscopy assists that are real but incremental rather than autonomy, and the Performance-Guided Surgery framing was oversold relative to what is cleared.","identifier":"abadf566-b528-4b44-be3e-418ca078e920","category":"surgical","publisher":{"@id":"https://deploy.report/#organization"}}}